Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 in obese/overweight chronic kidney disease (phase II, China)
ChiCTR2500106280Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UBT251 in chronic kidney disease (CKD), obesity and Overweight (4 arms), sponsored by Peking University First Hospital. Primary endpoint: Change from baseline in log-transformed UACR at 24 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
UBT251
03
Conditions
chronic kidney disease (CKD)obesityOverweight
Beyond the preview
Go deeper on ChiCTR2500106280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106280.